NCT00434239View on ClinicalTrials.gov

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2014

Conditions
Myelodysplasia
Interventions
DRUG

Lenalidomide + Ancestim

Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle

Trial Locations (1)

3002

Peter MacCallum Cancer Centre, East Melbourne

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Peter MacCallum Cancer Centre, Australia

OTHER